Over the last few years, blood-based biomarkers, mainly including Aβ42/40 and phosphorylated tau at different residues, have been shown to have reasonable diagnostic accuracy in distinguishing AD or MCI patients from non-affected controls [9,10,11,12]. The gene discussed is MAPT; the disease is Alzheimer disease.